DTC ad spending plummets by 18.4%

Advertising spending among pharmaceutical companies dropped 18.4 percent in 2008, from $5.3 billion to $4.3 billion, due in part to the bleak economic landscape and to a decrease in drugs on the market. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.